Connecticut Telemedicine Laws: License, Prescribing, Consent

Connecticut spent four years running its telehealth rules on temporary extensions — and then, in 2024, made almost all of them permanent. Add the Interstate Medical Licensure Compact finally becoming operational in March 2026, and Connecticut now has one of the more settled telehealth frameworks in the Northeast. The sharp edge that remains: a state-law bar on most telehealth prescribing of Schedule I–III controlled substances.

Licensure: CT license required, and the compact finally works

Care is governed by the law of the state where the patient sits, and a telehealth provider treating Connecticut patients must hold the relevant Connecticut license. The news is the compact: Connecticut adopted the IMLC back in 2022, but implementation lagged for years. Since March 15, 2026, the Department of Public Health issues Letters of Qualification, which means the expedited pathway is genuinely usable — both for out-of-state physicians seeking Connecticut licenses and for Connecticut physicians expanding outward.

One pathway quietly disappeared: the registration that let out-of-state mental and behavioral health providers treat Connecticut patients without full licensure sunset on June 30, 2025, and nothing has replaced it. Behavioral health groups that relied on registered out-of-state clinicians need those clinicians licensed now — the compact (or PSYPACT, for psychologists) is the way through. Section 19a-906(g) keeps on-call coverage, provider-to-provider consultation, and hospital orders outside the telehealth section's requirements, but it defines "health care provider" by Connecticut licensing chapters and creates no license exception for out-of-state clinicians. The medical practice act is explicit that a physician in an ongoing, regular, or contractual arrangement to provide diagnostic or treatment services electronically to anyone located in Connecticut needs a Connecticut license, wherever the physician lives; the main exception is a nonresident physician who, while outside the state, consults on an irregular basis with a Connecticut-licensed physician located in the state, or with a Connecticut medical school for educational or training purposes (Conn. Gen. Stat. § 20-9(d)). Subject to federal requirements, state licensing standards, and state telehealth law, a telehealth provider may practice from any location to a patient in any location (§ 19a-906(j)).

Prescribing: the strictest layer wins, and here the strict layer is state law

Connecticut doesn't require an in-person exam to form a treatment relationship — the telehealth encounter suffices if the provider uses real-time interactive communication or store-and-forward, has access to or knowledge of the patient's medical history and health record, meets the in-person standard of care, and gives the patient the provider's license number and contact information (§ 19a-906(b)(1)).

Controlled substances are a different story. Under § 19a-906(c), telehealth providers may not prescribe any Schedule I, II, or III controlled substance, with one exception: a Schedule II or III drug used as part of medication-assisted treatment, or to treat a psychiatric disability or substance use disorder, prescribed in a manner fully consistent with the federal Ryan Haight Act. Until June 30, 2025 that exception excluded opioids; P.A. 25-168, § 116 removed the opioid carve-out, so buprenorphine for opioid use disorder now fits within it. Schedule II–III opioids for pain, and any other Schedule II–III prescribing outside those purposes, remain barred by state law, whatever federal rules allow. Schedules IV–V aren't restricted by this section, and a Schedule II or III prescription issued under the exception must be submitted electronically.

Several other state duties apply to telehealth exactly as they do in person:

• State registration. Every practitioner who prescribes, administers or dispenses a controlled substance in Connecticut must hold a certificate of registration from the Commissioner of Consumer Protection, and a practitioner who prescribes controlled substances must also register for access to the state prescription drug monitoring program (Conn. Gen. Stat. § 21a-317).
• PDMP. Before prescribing more than a 72-hour supply of any controlled substance, the prescriber or an authorized agent must review the patient's record in the state's electronic prescription drug monitoring program, and must repeat the review at least every 90 days during continuous or prolonged treatment (annually for Schedule V nonnarcotic drugs) (§ 21a-254(j)(9)).
• Opioid limits. A first-time outpatient opioid prescription for an adult may not exceed a seven-day supply, and no opioid prescription for a minor may exceed a five-day supply. The prescriber may exceed those limits when, in the prescriber's professional judgment, more is needed for an acute medical condition, chronic pain, cancer-related pain or palliative care, and must document the triggering condition and that a non-opioid alternative was not appropriate. The limits do not apply to medications that treat opioid use disorder. With every opioid prescription, the prescriber must discuss the risks of addiction and overdose and encourage the patient to obtain an opioid antagonist (§ 20-14o).
• E-prescribing. A practitioner authorized to prescribe controlled substances must transmit controlled-substance prescriptions to the pharmacy electronically (§ 21a-249(b)). Listed exceptions include a temporary technological or electrical failure; a pharmacy outside Connecticut; and a supply of no more than five days when the patient could not obtain an electronically prescribed drug in time and the delay would harm the patient's condition. The practitioner documents the reason in the record. The exception for a practitioner who lacks the technology to e-prescribe does not apply to telehealth prescribing under § 19a-906(c) (§ 21a-249(c)). Medicare Part D separately requires at least 70 percent of Part D Schedule II–V prescriptions to be electronic under 42 CFR 423.160, subject to exceptions and waivers.

Federal law adds a separate layer for controlled substances. Under the temporary rule DEA and HHS published December 31, 2025 (90 FR 61301), which runs through December 31, 2026, a DEA-registered practitioner may prescribe Schedule II–V controlled substances after a real-time audio-video telemedicine encounter without a prior in-person evaluation, when the rule's other conditions are met; audio-only encounters qualify only for Schedule III–V narcotic medications approved by the FDA to treat opioid use disorder. Connecticut's Schedule I–III bar applies on top of that federal rule. See our DEA prescribing coverage.

If you run a telepsychiatry or medication-assisted treatment program, Connecticut is workable by design. If you run pain management, it isn't — plan for in-person prescribing of Schedule II–III drugs.

Consent

At the first telehealth interaction, the provider must explain how telehealth treatment works and what its limitations are, obtain the patient's consent, and document both in the record — revocations get documented too. Consent can come from a guardian, conservator, or authorized representative where applicable. HUSKY (Medicaid) layers on a written-consent expectation before services begin and annually thereafter, and electronic consent is acceptable there.

Medicaid: HUSKY covers video broadly, audio-only by design

HUSKY Health covers live video across its programs, with the 2025 shift to the dedicated telemedicine E/M codes (98001–98007). Audio-only is covered for services the Department of Social Services designates — the statute limits it to clinically appropriate situations where audiovisual isn't possible or the member can't otherwise access comparable services, and the eligible-code list has been growing. Store-and-forward reimbursement arrived for e-consults at the start of 2025. The patient's home works as an originating site, with some clinic-setting nuances for medical (as opposed to behavioral) services. Medicaid reimburses telehealth to the same extent as in-person care.

Remote patient monitoring sits in the statutory definition of telehealth, but we found no explicit HUSKY reimbursement pathway for it — verify with DSS before building an RPM program around Medicaid revenue.

Private insurance: parity is permanent

Connecticut's coverage parity predates COVID (§§ 38a-499a, 38a-526a): individual and group policies must cover advice, diagnosis, care or treatment provided through telehealth to the extent they cover it when provided in person by a health care provider licensed in the state, subject to the same terms and conditions as the policy's other benefits. A policy may not exclude a service solely because it is provided only through telehealth, where telehealth is appropriate, and it need not pay technical fees or technical costs. Carriers may conduct utilization review for telehealth services only in the same manner, and with the same clinical review criteria, as for the same service in person. Neither section addresses out-of-network providers, so the policy's ordinary network terms apply.

What changed in 2024 is that the COVID-era enhancements stopped being temporary. Under PA 24-110, a health carrier may not reduce its reimbursement for a covered service appropriately provided through telehealth because it was delivered by telehealth rather than in person (§ 38a-477mm). The same act rewrote the telehealth definition, which now excludes only fax, texting and email, so audio-only telephone counts. It also made permanent the rule that a telehealth provider may practice from any location to a patient in any location, subject to federal requirements, state licensing standards, and state telehealth law (§ 19a-906(j)). Before providing care, a telehealth provider must determine whether the patient has coverage and will use it, and must disclose the cost to a patient who will pay directly or in part. The provider must then accept as payment in full the Medicare amount for a patient without coverage for the service, the plan's payment plus the patient's cost sharing for a covered patient, or an amount the patient and provider mutually agree to (§ 19a-906(i)). A separate provision bars telehealth providers and hospitals from charging a facility fee for telehealth services (§ 19a-906(h)). The full payer picture is in our reimbursement guide.

What to watch

Connecticut's framework is stable enough that the watch-list is short: whether the legislature revives an out-of-state behavioral health registration (the June 2025 sunset left a real gap), how the DEA's pending special-registration rule interacts with the state's Schedule II–III exception, and a lingering ambiguity around Schedule II refills for established patients that the state hasn't cleanly resolved. Verify current requirements with DPH and DSS before acting, and see the national overview for how Connecticut compares to its neighbors.